期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 53, 期 15, 页码 5886-5889出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm100380k
关键词
-
资金
- Apotex Incorporation, Canada
This report presents that Deferiprone, the only clinically used 3-hydroxypyridin-4-one (HPO), is able to penetrate the blood-brain barrier (BBB) in guinea pigs, whereas its glucosylated analogue is unable to do so. This finding is contrary to published information suggesting that the glucosylation of HPOs is a viable means of enhancing the brain uptake of this group of compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据